Talzenna bags EU approval for gBRCA-mutated breast cancer
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
Read More
Tag: Talzenna
Pfizer’ Talzenna leads latest CHMP highlights
Thirteen medicines were recommended for approval at the committee’s April 2019 meeting.
Read More
Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
